Health Care • Medical/Dental Instruments
$21.79 ▲ +0.24
(+1.11%)
MKT CAP: $291.6M • VOL: 121.8K
52W L $9 52W H $23
ROARABLE / RQD
D+ • 55/100
PIOTROSKI
6 / 9
ANIK // SEC EDGAR XBRL STANDARDIZED FINANCIAL STATEMENTS (FA <GO>)
| LINE ITEM (USD / %) | FY 2025
FILED 2025-12-31 | FY 2024
FILED 2024-12-31 | FY 2023
FILED 2023-12-31 |
|---|---|---|---|
| Revenue (Total Sales) | $112.8M | $119.9M | $120.8M |
| YoY Revenue Growth % | -5.9% | -0.7% | — |
| Gross Profit | $63.8M | $76.0M | — |
| Gross Margin % | 56.6% | 63.4% | — |
| Research & Development (R&D) | — | — | — |
| Operating Income (EBIT) | -$11.1M | -$5.1M | $844.0K |
| Operating Margin % | -9.8% | -4.3% | 0.7% |
| Net Income (GAAP) | -$11.0M | -$56.0M | -$83.0M |
| EBITDA (Normalized) | -$5.6M | $1.1M | — |
| Diluted EPS ($/sh) | — | — | — |
| Operating Cash Flow (OCF) | $11.2M | $5.4M | -$1.8M |
| Capital Expenditures (CapEx) | $6.8M | $7.7M | — |
| Free Cash Flow (FCF) | $4.4M | -$2.3M | -$1.8M |
| FCF Margin % | 3.9% | -1.9% | -1.5% |
| Return on Invested Capital (ROIC %) | -10.2% | -4.1% | — |
| Cash & Short-Term Equivalents | $57.5M | $55.6M | — |
| Total Debt (Short + Long Term) | — | — | — |
| Total Stockholders' Equity | $143.5M | $154.0M | — |
NO QUARTERLY 10-Q XBRL STATEMENTS AVAILABLE IN CURRENT CACHE FOR ANIK.